Zealand Pharma A/S (OTCMKTS:ZLDPF) Announces Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its quarterly earnings data on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.19, Zacks reports. Zealand Pharma A/S had a negative return on equity of 18.49% and a negative net margin of 1,375.16%.

Zealand Pharma A/S Stock Performance

ZLDPF opened at $108.30 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The company’s 50 day simple moving average is $102.06 and its two-hundred day simple moving average is $113.67. Zealand Pharma A/S has a 1-year low of $67.58 and a 1-year high of $141.74. The firm has a market capitalization of $7.69 billion, a price-to-earnings ratio of -44.57 and a beta of 0.88.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ZLDPF shares. Cantor Fitzgerald raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, January 21st. JPMorgan Chase & Co. started coverage on shares of Zealand Pharma A/S in a research note on Friday, November 8th. They issued an “overweight” rating on the stock.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.